The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000839303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
22/06/2026
Date registered
Help: Date registered
10/07/2026
Date last updated
Help: Date last updated
10/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
10/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Upadacitinib in addition to steroids for the initial treatment of acute severe ulcerative colitis (ASUC)
Scientific title
Upadacitinib in addition to steroids for the initial treatment of acute severe ulcerative colitis (ASUC): Evaluating the efficacy, safety and feasibility of upadacitinib in addition to steroids for the initial treatment of ASUC
Additional trial identifiers [1] 317144 0
CT32890
Universal Trial Number (UTN)
Trial acronym
U-SENSE
Related trial records

Health condition
Health condition(s) studied:
acute severe ulcerative colitis 341722 0
Condition category
Condition code
Oral and Gastrointestinal 337799 337799 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Upadacitinib 45mg tablet orally once daily for the first 5 days of admission. This intervention will be in addition to standard of care treatment with intravenous hydrocortisone, which will be administered at a dose of 100mg 4 times daily. The clinical trial team will administer the trial medication daily for the duration of the study, and adherence will be monitoring daily using electronic medication record.

Intervention code [1] 333912 0
Treatment: Drugs
Description of the comparator or control
The comparator group will be treated using standard of care treatment, which is intravenous steroids alone
Control group
Active

Outcomes
Primary outcome [1] 345244 0
Efficacy: clinical response
Timepoint [1] 345244 0
Day 5 of admission
Primary outcome [2] 345245 0
Safety: adverse events
Timepoint [2] 345245 0
Days 0 to 35 from date of admission
Primary outcome [3] 345246 0
Feasibility: Completion of the study protocol requirements
Timepoint [3] 345246 0
Day 35 following date of admission
Secondary outcome [1] 461106 0
Clinical response criteria
Timepoint [1] 461106 0
Day 3 of admission
Secondary outcome [2] 461107 0
Clinical response criteria
Timepoint [2] 461107 0
Between day 0 and day 5 of admission
Secondary outcome [3] 461108 0
Clinical response criteria
Timepoint [3] 461108 0
Between day 0 and day 5 of admission
Secondary outcome [4] 464197 0
Clinical response criteria
Timepoint [4] 464197 0
Between day 0 and day 5 of admission
Secondary outcome [5] 464449 0
Biochemical response
Timepoint [5] 464449 0
Daily from day 0-5 of admission
Secondary outcome [6] 464450 0
Biochemical response
Timepoint [6] 464450 0
Daily from day 0-5 of admission
Secondary outcome [7] 464451 0
Biochemical response
Timepoint [7] 464451 0
Between day 0 and 5 of admission
Secondary outcome [8] 464452 0
Radiological response
Timepoint [8] 464452 0
Between day 0 and 5 of admission
Secondary outcome [9] 464453 0
Total cost of hospitalisation of patients
Timepoint [9] 464453 0
Discharge day of index hospitalisation
Secondary outcome [10] 464456 0
Total duration of hospitalisation of patients
Timepoint [10] 464456 0
Discharge day of index hospitalisation
Secondary outcome [11] 464473 0
Exploratory outcome: Biomarker testing
Timepoint [11] 464473 0
Between day 0 and 5 of admission
Secondary outcome [12] 464474 0
Exploratory outcome: global coagulation studies
Timepoint [12] 464474 0
Between day 0 and 5 of admission

Eligibility
Key inclusion criteria
a). Aged between 18 to 65
b) Have ability to give written informed consent;
c) Have confirmed ASUC defined by the modified Truelove and Witts criteria;
d) Being admitted for management with intravenous corticosteroids;
e) Laboratory assessments at screening within the following parameters:
a. Haemoglobin greater than or equal to 80 g/L
b. Absolute neutrophil count greater than or equal to 1.5 x 10^3/µL
c. Absolute lymphocyte count greater than or equal to 0.5 x 10^3/µL
d. Platelets greater than or equal to 100 x 10^3/µL
e. Aspartate aminotransferase and alanine aminotransferase less than or equal to 2 x upper limit of normal (ULN)
f. Total bilirubin less than or equal to 2 x ULN
g. Alkaline phosphatase less than 3 x ULN
h. Estimated glomerular filtration rate greater than 60 mL/min
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
a) Evidence of fulminant UC (toxic megacolon as evidenced by transverse colon diameter greater than or equal to 60mm and one of: fever [T greater than or equal to 37.80C], tachycardia [pulse rate greater than or equal to 90 beats per minute]);
b) Pregnant or breastfeeding;
c) Women of reproductive potential unless using effective contraception during treatment and for 4 weeks following the final dose of upadacitinib.
d) Evidence of infection on clinical evaluation;
e) History of solid organ or haematological malignancy, significant cardiorespiratory disease, severe hepatic impairment, thrombophilia or thromboembolic disorder;
f) Any absolute contraindication to steroids;
g) History of ischaemic colitis, radiation colitis, ileoanal pouch;
h) History of ileostomy or colostomy;
i) History of HIV, hepatitis B, hepatitis C, or active or latent tuberculosis;
j) History of symptomatic herpes zoster within 16 weeks of randomization, or any history of disseminated herpes simplex, disseminated herpes zoster, ophthalmic zoster, or varicella zoster virus central nervous system infections;
k) History of faecal microbiota transplantation within 2 weeks of presentation;
l) Inability to take oral medications;
m) Concomitant treatment with strong CYP3A4 inhibitors or inducers;
n) Patients who have received live or attenuated vaccines within 28 days;
o) Be part of any other interventional trial;
p) Any unstable or chronic medical condition, including, but not limited to, cardiac, pulmonary, hepatic (e.g., cirrhosis), or psychiatric problem (including alcohol or drug abuse) that, in the opinion of the investigator, would make the participant unsuitable for the study or would prevent compliance with the study protocol

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC

Funding & Sponsors
Funding source category [1] 321728 0
Charities/Societies/Foundations
Name [1] 321728 0
Gastroenterological Society of Australia
Country [1] 321728 0
Australia
Primary sponsor type
University
Name
The University of Melbourne
Address
Country
Australia
Secondary sponsor category [1] 324779 0
None
Name [1] 324779 0
Address [1] 324779 0
Country [1] 324779 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320261 0
Austin Health Human Research Ethics Committee
Ethics committee address [1] 320261 0
Ethics committee country [1] 320261 0
Australia
Date submitted for ethics approval [1] 320261 0
28/08/2025
Approval date [1] 320261 0
11/11/2025
Ethics approval number [1] 320261 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149926 0
Prof Mayur Garg
Address 149926 0
Northern Health, 185 Cooper Street, Epping, Victoria 3076
Country 149926 0
Australia
Phone 149926 0
+61 3 8405 2290
Fax 149926 0
Email 149926 0
Contact person for public queries
Name 149927 0
Dr Maria Bishara
Address 149927 0
Northern Health, 185 Cooper Street, Epping, Victoria 3076
Country 149927 0
Australia
Phone 149927 0
+61 384058000
Fax 149927 0
Email 149927 0
Contact person for scientific queries
Name 149928 0
Dr Maria Bishara
Address 149928 0
Northern Health, 185 Cooper Street, Epping, Victoria 3076
Country 149928 0
Australia
Phone 149928 0
+61 384058000
Fax 149928 0
Email 149928 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.